In the early 1990's, the United States' diet craze and pursuit for thinness found a new drug of choice, Fen-Phen, guaranteed to help users finally lose weight. Two drugs, fenfluramine and phentermine, came up with the Fen-Phen drink. Fenfluramine works in the body by releasing extra amounts of serotonin, which is the neurotransmitter in charge of feelings of satiety and fullness. Phentermine, a stimulating, would counteract the sleepiness inducing qualities of a surge of the hormone serotonin. The two drugs had fewer aspect effects when that than when taken individually. Despite the fact that America had not recently been diet drug crazy since the amphetamine use of the 1960's, Fen-Phen appeared like a different sort of weight loss aid. A new 1983 study over the course of four years found that obese patients (those weighing 200 pounds or more) lost thirty-two pounds on average when taking the drug drink. This research, along with the medical community's support and users' results, allowed Fen-Phen to dominate the diet medication market in the 1990's.
In 1996 alone, there have been 18 million prescriptions written for Fen-Phen. American Residence Products, the company accountable for manufacturing phenq, made Fen-Phen offered to the public without proper warnings and part effect information. In April 1996, American Home Goods also started producing Redux, a diet drug that was approved to sell despite a 5-3 election by a scientific panel against its approval. In just a year and a 50 percent after its approval, 2. 5 million prescriptions for Redux had already recently been written for dieters.
Within 1997, the Mayo Medical center released a study with regards to the serious side effects and everlasting health problems resulting from the employment of Fen-Phen. The most common side-effect of the drug was heart valve defects, more specifically aortic and mitral valves. The center problems caused by Fen-Phen would require risky heart surgery. Additional problems included primary pulmonary hypertension, a devastating disease in which stress in the pulmonary artery increases to dangerous levels and creates additional cardiac stress. Soon after, in September 1997, the Food and Drug Administration (FDA) drawn this diet drugs from the market. With this point, Us Home Products had made about $200 million from cashing in on the diet program craze.